To view associated reagents, ancillaries and bulks, please visit the Roche Tissue Diagnostics reagent catalog.
Breast cancer remains a significant scientific, clinical and societal challenge claiming more than 600,000 lives worldwide each year. Each cancer diagnosis is as distinct as the individual it affects. Understanding the diversity in breast cancer allows for patient stratification and more personalized treatment pathways. Biomarkers provide objective observations of tumor profiles, including prognostic and predictive information leading to more guided measures of patient management.
Roche is committed to contributing to improved outcomes in breast cancer by bringing you the most comprehensive panel of breast cancer diagnostic assays so that you can deliver personalized, confident results for each patient.
The Roche breast cancer diagnostic assays provide you with a complete portfolio of the critical markers you need to deliver the right test for each patient in the shortest possible time.
Specific and sensitive rabbit monoclonal antibodies, best-in-class probes, and powerful detection systems help you diagnose precisely and confidently.
Our comprehensive breast cancer workflow solution delivers fully automated assays on market-leading platforms, with digital pathology and workflow solutions that free resources, reduce labor costs, and reduce time to result.
The use of pre-diluted PATHWAY HER2 (4B5),14 in combination with the fully automated VENTANA BenchMark IHC/ISH slide staining instrument, standardizes all IHC processes from baking through staining, and reduces the possibility of human error. It also minimized inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods.
The new VENTANA HER2 Dual ISH assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene amplification. This assay helps identify breast cancer patients eligible for treatment with HERCEPTIN® (trastuzimab)
Using the right test to determine PD-L1 status for immunotherapy options is important. The FDA approved VENTANA PD-L1 (SP142) Assay gives you the confidence to reliably identify triple-negative breast cancer (TNBC) patients eligible for TECENTRIQ.®11,12
The novel VENTANA PD-L1 (SP142) Assay is easy to score and the first with FDA-approval to evaluate breast cancer patients for PD-L1 expression using immune cell staining and scoring within the tumor microenvironment. The assay provides you with information that multidisciplinary teams need to guide immunotherapy decisions in TNBC.
CONFIRM ER (SP1) is an FDA cleared antibody indicated as an aid in patient management, prognosis, and the prediction of therapy outcomes in breast cancer.6
CONFIRM PR (1E2) is an FDA cleared antibody indicated as an aid in patient management, prognosis, and the prediction of therapy outcomes in breast cancer.9